Bone marrow provides an environment that prevents suppression oftherapeutic graft-vs.-tumor immunity by regulatory T cells

OncoImmunology

Volumn 2, Issue 7, 2013, Pages

  Guichelaar, Teun ^a   Mutis, Tuna ^b  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Bone marrow; Graft versus host disease; Graft versus tumor; Lymphocyte infusion; Regulatory T cell

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; TRANSCRIPTION FACTOR FOXP3;

ARTICLE; BONE MARROW CELL; CANCER PATIENT; CD4+ CD25+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOKINE RESPONSE; DONOR LYMPHOCYTE INFUSION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; IMMUNOREACTIVITY; IMMUNOSUPPRESSIVE TREATMENT; MULTIPLE MYELOMA; NONHUMAN; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TH17 CELL; TREATMENT OUTCOME; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

EID: 84886944756     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.24659     Document Type: Article

References (9)

1. Curiel TJ. Tregs and rethinking cancer immunotherapy. J Clin Invest 2007; 117:1167-74; PMID:17476346; http://dx.doi.org/10.1172/JCI31202
2. Maury S, Lemoine FM, Hicheri Y, Rosenzwajg M, Badoual C, CheraÏ M, et al. CD4+CD25+ regulatory T cell depletion improves the graft-versus-tumor effect of donor lymphocytes after allogeneic hematopoietic stem cell transplantation. Sci Transl Med 2010; 2:41ra52; PMID:20650872; http://dx.doi.org/10.1126/scitranslmed. 3001302
3. Brunstein CG, Miller JS, Cao Q, McKenna DH, Hippen KL, Curtsinger J, et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood 2011; 117:1061-70; PMID:20952687; http://dx.doi.org/10.1182/blood-2010-07-293795
4. Koenen HJ, Smeets RL, Vink PM, van Rijssen E, Boots AM, Joosten I. Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood 2008; 112:2340-52; PMID:18617638; http://dx.doi. org/10.1182/blood-2008-01-133967
5. Sharma MD, Hou DY, Baban B, Koni PA, He Y, Chandler PR, et al. Reprogrammed foxp3(+) regulatory T cells provide essential help to support crosspresentation and CD8(+) T cell priming in naive mice. Immunity 2010; 33:942-54; PMID:21145762; http:// dx.doi.org/10.1016/j.immuni.2010.11.022
6. Edinger M, Hoffmann P, Ermann J, Drago K, Fathman CG, Strober S, et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 2003; 9:1144-50; PMID:12925844; http://dx.doi.org/10.1038/nm915
7. Heier I, Hofgaard PO, Brandtzaeg P, Jahnsen FL, Karlsson M. Depletion of CD4+ CD25+ regulatory T cells inhibits local tumour growth in a mouse model of B cell lymphoma. Clin Exp Immunol 2008; 152:381-7; PMID:18341610; http://dx.doi.org/10.1111/j.1365- 2249.2008.03642.x
8. Trenado A, Charlotte F, Fisson S, Yagello M, Klatzmann D, Salomon BL, et al. Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. J Clin Invest 2003; 112:1688-96; PMID:14660744
9. Guichelaar T, Emmelot ME, Rozemuller H, Martini B, Groen RW, Storm G, et al. Human regulatory T cells do not suppress the antitumor immunity in the bone marrow: a role for bone marrow stromal cells in neutralizing regulatory T cells. Clin Cancer Res 2013; 19:1467-75; PMID:23382115; http://dx.doi. org/10.1158/1078-0432.CCR-12-2177.